2015-12327. Importer of Controlled Substances Registration: Mylan Pharmaceuticals, Inc.  

  • Start Preamble

    ACTION:

    Notice of registration.

    SUMMARY:

    Mylan Pharmaceuticals, Inc. applied to be registered as an importer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Mylan Pharmaceuticals, Inc. registration as an importer of those controlled substances.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    By notice dated January 9, 2015, and published in the Federal Register on January 26, 2015, 80 FR 3980, Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Road, Morgantown, West Virginia 26505 applied to be registered as an importer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

    The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of Mylan Pharmaceuticals, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of the basic classes of controlled substances:

    Controlled substanceSchedule
    Amphetamine (1100)II
    Methylphenidate (1724)II
    Oxycodone (9143)II
    Hydromorphone (9150)II
    Methadone (9250)II
    Morphine (9300)II
    Fentanyl (9801)II

    The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company's own domestically-manufactured FDF. This analysis is required to allow the company to export domestically-manufactured FDF to foreign markets.

    Start Signature

    Dated: May 15, 2015.

    Joseph T. Rannazzisi,

    Deputy Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2015-12327 Filed 5-20-15; 8:45 am]

    BILLING CODE P

Document Information

Published:
05/21/2015
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of registration.
Document Number:
2015-12327
Pages:
29337-29337 (1 pages)
Docket Numbers:
Docket No. DEA-392
PDF File:
2015-12327.pdf